Opportunity
Federal Register #2026-23367
FDA determination on M.V.I. PEDIATRIC injection and potential generic applications
Buyer
Food and Drug Administration
Posted
November 17, 2026
Identifier
2026-23367
The FDA issued a regulatory determination on M.V.I. PEDIATRIC, a pediatric multiple-vitamin injection used with parenteral nutrition. - Government agency: Department of Health and Human Services, Food and Drug Administration (FDA); no specific office is identified. - Product and formulation: M.V.I. PEDIATRIC (Multiple Vitamins for Injection), NDA 018920, for pediatric patients up to 11 years receiving parenteral nutrition. Each vial contains ascorbic acid 80 mg, biotin 0.02 mg, cyanocobalamin 0.001 mg, dexpanthenol 5 mg, ergocalciferol 0.01 mg, folic acid 0.14 mg, niacinamide 17 mg, phytonadione 0.2 mg, pyridoxine hydrochloride 1 mg, riboflavin 5′-phosphate sodium 1.4 mg, thiamine hydrochloride equivalent to 1.2 mg base, vitamin A 0.7 mg, and vitamin E 7 mg. - OEM/application holder: Hospira Inc. is identified as the holder of the original drug application. - Apotex, Inc. submitted the citizen petition that prompted the FDA determination; it is not identified as the product manufacturer. - FDA determined the product was not withdrawn from sale for reasons of safety or effectiveness and will retain it on the Orange Book Discontinued Drug Product List. FDA may approve qualifying abbreviated new drug applications (ANDAs) referencing the formulation if other legal and regulatory requirements are met. - This is a regulatory notice, not a request to purchase goods or services; no quantities, contract value, or performance period are specified.
Description
The FDA determined that M.V.I. PEDIATRIC, a multiple-vitamin injection, was not withdrawn from sale for reasons of safety or effectiveness. The determination allows FDA to approve abbreviated new drug applications for the corresponding formulation, provided all other legal and regulatory requirements are met. The notice identifies the formulation’s vitamin ingredients and strengths and states that the product will remain listed in the Orange Book’s Discontinued Drug Product List.